Recently, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort NeuroTech") held its result-summary meeting of prospective, multi-center, randomized controlled clinical study for the products Tubridge Revascularization Device in Shanghai. Mr. Zhiyong Xie, General Manager of MicroPort NeuroTech, and other 13 specialists from various neurologist centers participated in the meeting.
Mr. Zhiyong Xie presided over the meeting. Professor Jianmin Liu from Changhai Hospital commented on the process of clinical trial; and Mr. Xiulong Yue, manager of CRO Corporation summarized the overall procedure of the clinical trial.
During the meeting, professors and experts actively discussed the clinical trial results including the integrity of the data and focal point for the next second-stage clinical trial. In addition, various professors from different hospitals talked about several difficult surgical cases. Dr. Jianmin Liu pointed out that Tubridge Revascularization Device is actually the first Flow diverter indicated for treatment of large aneurysms domestically. The device effectively addresses the recurrence rate problems from traditional stent-assisted coil embolization method. In addition, this is also the first prospective, multi-center, randomized controlled clinical study in the cerebral neuroscience field in China, which has a significant implication in the field. All the participating members affirmed their positive evaluation in the safety and efficacy features on this Tubridge Revascularization Device.
"Tubridge Revascularization Device is independently developed by MicroPort NeuroTech. It's the next generation neurovascular product for treating large cerebral aneurysm in China", said Mr. Zhiyong Xie, General Manager of MicroPort NeuroTech, "The clinical study is the largest one in the field of neurovascular-related disease in China and strictly followed through the international standard procedure. MicroPort NeuroTech will continuously making effort on pushing forward this project."